For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.
Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...
A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...
Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.
What you need to know Two popular diabetes and weight loss drugs among some may be linked to reduced risk of mental, cognitive and addiction conditions. The study authors and independent experts ...
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...
Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...
THESE MEDICATIONS ARE MOSTLY KNOWN FOR TREATING DIABETES AND OBESITY.. BUT THE F-D-A HAS APPROVED THEM FOR PREVENTING HEART ...
When it comes to medically assisted weight loss, there’s two main schools of thought: either weight loss drugs, like the ...
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback